Clinical Trials Register

Summary
EudraCT Number:	2017-001551-31
Sponsor's Protocol Code Number:	BGB-3111-304
National Competent Authority:	Spain - AEMPS
Clinical Trial Type:	EEA CTA
Trial Status:	Ongoing
Date on which this record was first entered in the EudraCT database:	2017-11-02
Trial results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

Spain - AEMPS

A.2

EudraCT number

2017-001551-31

A.3

Full title of the trial

An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Estudio de fase III, internacional, abierto y aleatorizado de BGB-3111 en comparación con bendamustina más rituximab, en pacientes con leucemia linfocítica crónica o linfoma linfocítico de células pequeñas no tratados previamente

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

A Phase 3 Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Estudio en fase III de BGB-3111 en comparación con bendamustina más rituximab, en pacientes con leucemia linfocítica crónica o linfoma linfocítico de células pequeñas no tratados previamente

A.4.1

Sponsor's protocol code number

BGB-3111-304

A.7

Trial is part of a Paediatric Investigation Plan

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	BeiGene, Ltd.
B.1.3.4	Country	United States
B.3.1 and B.3.2	Status of the sponsor	Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	BeiGene, Ltd.
B.4.2	Country	United States
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	BeiGene, Ltd.
B.5.2	Functional name of contact point	US
B.5.3	Address:
B.5.3.1	Street Address	US
B.5.3.2	Town/ city	US
B.5.3.3	Post code	US
B.5.3.4	Country	United States
B.5.4	Telephone number	+34900 811 335
B.5.6	E-mail	praregulatoryaffairs@prahs.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	No
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	BGB-3111
D.3.2	Product code	BGB-3111
D.3.4	Pharmaceutical form	Capsule
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	not yet established
D.3.9.1	CAS number	1691249-45-2
D.3.9.2	Current sponsor code	BGB-3111
D.3.9.4	EV Substance Code	SUB184615
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	80
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 2
D.1.2 and D.1.3	IMP Role	Comparator
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	Levact
D.2.1.1.2	Name of the Marketing Authorisation holder	Astellas Pharma GmBH
D.2.1.2	Country which granted the Marketing Authorisation	Germany
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Bendamustine
D.3.4	Pharmaceutical form	Powder for concentrate for solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	BENDAMUSTINE HYDROCHLORIDE
D.3.9.1	CAS number	3543-75-7
D.3.9.4	EV Substance Code	SUB00696MIG
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	100
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 3
D.1.2 and D.1.3	IMP Role	Comparator
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	MabThera
D.2.1.1.2	Name of the Marketing Authorisation holder	Roche Registration Ltd
D.2.1.2	Country which granted the Marketing Authorisation	European Union
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Rituximab
D.3.4	Pharmaceutical form	Concentrate for solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	RITUXIMAB
D.3.9.1	CAS number	174722-31-7
D.3.9.4	EV Substance Code	SUB12570MIG
D.3.10	Strength
D.3.10.1	Concentration unit	mg/ml milligram(s)/millilitre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	10
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	No
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	Yes
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Leucemia linfocítica crónica o linfoma linfocítico de células pequeñas no tratados previamente.

E.1.1.1

Medical condition in easily understood language

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Leucemia linfocítica crónica o linfoma linfocítico de células pequeñas.

E.1.1.2

Therapeutic area

Diseases [C] - Cancer [C04]

MedDRA Classification

E.1.2 Medical condition or disease under investigation

E.1.2	Version	20.0
E.1.2	Level	LLT
E.1.2	Classification code	10003946
E.1.2	Term	B-Lymphocytic, CLL (Kiel Classification)
E.1.2	System Organ Class	100000004864

E.1.2 Medical condition or disease under investigation

E.1.2	Version	20.0
E.1.2	Level	LLT
E.1.2	Classification code	10041152
E.1.2	Term	Small lymphocytic lymphoma, consistent with CLL (Working Formulation)
E.1.2	System Organ Class	100000004864

E.1.3

Condition being studied is a rare disease

E.2 Objective of the trial

E.2.1

Main objective of the trial

To compare efficacy between treatment groups in cohort 1, as measured by progression-free survival determined by independent central review

Comparar la eficacia entre grupos de tratamiento en la cohorte 1 con respecto a la supervivencia sin progresión determinada mediante revisión central independiente.

E.2.2

Secondary objectives of the trial

To evaluate efficacy in cohort 1, as measured by the following:
o Overall response rate determined by independent central review and by investigator assessment
o Overall survival
o Duration of response determined by independent central review and by investigator assessment
o Progression-free survival determined by investigator assessment
o Patient-reported outcomes
• To evaluate efficacy in cohort 2 (patients with del[17p]), as measured by the following:
o Overall response rate determined by independent central review
o Overall survival
o Progression-free survival determined by independent central review
o Duration of response determined by independent central review
• To compare safety between the treatment groups in cohort 1
• To evaluate pharmacokinetics of BGB-3111

• Evaluar la eficacia en la cohorte 1 con respecto a lo siguiente:
o Tasa de respuesta global conforme a la revisión central independiente y a la evaluación del investigador.
o Supervivencia global.
o Duración de la respuesta conforme a la revisión central independiente y a la evaluación del investigador.
o Supervivencia sin progresión conforme a la evaluación del investigador.
o Resultados notificados por el paciente.
• Evaluar la eficacia en la cohorte 2 (pacientes con la del[17p]), con respecto a lo siguiente:
o Tasa de respuesta global conforme a la revisión central independiente.
o Supervivencia global.
o Supervivencia sin progresión conforme a la revisión central independiente.
o Duración de la respuesta conforme a la revisión central independiente.
• Comparar la seguridad entre los grupos de tratamiento en la cohorte 1.
• Evaluar la farmacocinética de BGB-3111.

E.2.3

Trial contains a sub-study

E.3

Principal inclusion criteria

1. Unsuitable for chemoimmunotherapy with FCR in the opinion of the investigator
2. Confirmed diagnosis of CD20-positive CLL or SLL that meets the CLL criteria (Hallek et al, 2008)
3. Binet Stage C disease, or Binet Stage B or A disease requiring treatment as defined by at least one of the criteria (Hallek et al, 2008)
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
5. Life expectancy ≥ 6 months
6. Adequate bone marrow function
7. Patient must have adequate organ function
8. Female patients of childbearing potential must practice highly effective methods of contraception initiated prior to first dose of study drug, for the duration of the study, and for ≥ 90 days after the last dose of BGB-3111, 3 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer.
9. Male patients are eligible if vasectomized or if they agree to the use of barrier contraception with other methods described above during the study treatment period and for ≥ 90 days after the last dose of BGB-3111 or 3 months after the last dose of bendamustine whichever is longer.
10. Ability to provide written informed consent and can understand and comply with the requirements of the study

1. No ser aptos para recibir quimioinmunoterapia con FCR en opinión del investigador
2. Diagnóstico confirmado de LLC o LLCP CD20+ de acuerdo con los criterios del LLC (Hallek et al., 2008)
3. Enfermedad en estadio C de Binet o enfermedad en estadios A o B de Binet, que requieren tratamiento por cumplirse al menos uno de los criterios (Hallek et al., 2008)
4. Estado funcional del Grupo Oncológico Cooperativo del Este (ECOG) de 0, 1 o 2
5. Esperanza de vida ≥6 meses
6. Función de la médula ósea adecuada
7. Los pacientes deben tener una función orgánica adecuada
8. Las mujeres en edad fértil deben utilizar métodos anticonceptivos muy eficaces desde antes de la primera dosis del fármaco del estudio, durante todo el estudio y en un plazo ≥90 días tras la última dosis de BGB-3111, 3 meses tras la última dosis de bendamustina o 12 meses tras la última dosis de rituximab, lo que suponga más tiempo
9. Los pacientes varones son aptos si tienen hecha una vasectomía o aceptan el uso de anticonceptivos de barrera junto con otros de los métodos descritos anteriormente durante el período de tratamiento del estudio y en un plazo ≥90 días tras la última dosis de BGB-3111 o 3 meses tras la última dosis de bendamustina, lo que suponga más tiempo
10. Capacidad de proporcionar el consentimiento informado por escrito y de entender y cumplir los requisitos del estudio

E.4

Principal exclusion criteria

1. Previous systemic treatment for CLL/SLL
2. Known prolymphocytic leukemia or history of, or currently suspected, Richter’s transformation
3. Clinically significant cardiovascular disease
4. Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast
5. History of severe bleeding disorder
6. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
7. Severe or debilitating pulmonary disease
8. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
9. Active fungal, bacterial and/or viral infection requiring systemic therapy
10. Known central nervous system involvement by leukemia or lymphoma
11. Underlying medical conditions that, in the investigator’s opinion, will render the administration of study drug hazardous or obscure the interpretation of toxicity or AEs
12. Known infection with HIV, or serologic status reflecting active hepatitis B or C infection
13. Major surgery within 4 weeks of the first dose of study drug
14. Pregnant or lactating women
15. Vaccination with a live vaccine within 35 days prior to the first dose of study drug
16. Ongoing alcohol or drug addiction
17. Hypersensitivity to BGB-3111, bendamustine, or rituximab or any of the other ingredients of the study drugs
18. Requires ongoing treatment with a strong CYP3A inhibitor or inducer
19. Concurrent participation in another therapeutic clinical trial.

E.4 CRITERIOS PRINCIPALES DE EXCLUSIÓN
1. Tratamiento sistémico previo para la LLC/LLCP
2. Leucemia prolinfocítica conocida o transformación de Richter pasada, presunta o en curso
3. Enfermedad cardiovascular de importancia clínica
4. Neoplasia maligna en los 3 años anteriores, excepto carcinoma basocelular o espinocelular, cáncer superficial de vejiga o carcinoma in situ del cuello uterino o de la mama tratados con intención curativa
5. Antecedentes de trastornos hemorrágicos graves
6. Antecedentes de accidente cerebrovascular o hemorragia intracraneal en los 6 meses previos a la primera dosis del fármaco del estudio
7. Neumopatía grave o debilitante
8. Incapacidad para tragar las cápsulas o enfermedad que afecte de forma significativa al funcionamiento gastrointestinal, por ejemplo, síndrome de malabsorción, resección gástrica o del intestino delgado, intervenciones de cirugía bariátrica, enfermedad inflamatoria intestinal sintomática u obstrucción intestinal parcial o total
9. Infecciones micóticas, bacterianas y/o virales activas que requieran tratamiento sistémico
10. Afectación conocida del sistema nervioso central por la leucemia o el linfoma
11. Enfermedades subyacentes que, en opinión del investigador, hagan que la administración del fármaco del estudio sea peligrosa u oculte la interpretación de la toxicidad o los AA
12. Infección conocida por el VIH o estado serológico que refleja una infección activa por el virus de la hepatitis B o C
13. Intervención de cirugía mayor en las 4 semanas previas a la primera dosis del fármaco del estudio
14. Mujeres embarazadas o en período de lactancia
15. Administración de una vacuna con microbios vivos en los 35 días previos a la primera dosis del fármaco del estudio
16. Alcoholismo o drogadicción en curso
17. Hipersensibilidad a BGB-3111, bendamustina, rituximab o a cualquiera de los demás componentes de los fármacos del estudio
18. Necesidad de tratamiento con un inhibidor o inductor potente de CYP3A
19. Participación simultánea en otro ensayo clínico terapéutico

E.5 End points

E.5.1

Primary end point(s)

The primary endpoint is progression-free survival in cohort 1 (patients without del[17p]) determined by independent central review using the iwCLL guidelines with modification for treatment-related lymphocytosis, and defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

El criterio de valoración principal es la supervivencia sin progresión en la cohorte 1 (pacientes sin del[17p]) conforme a la revisión central independiente utilizando las directrices del Grupo de trabajo internacional sobre leucemia linfocítica crónica (iwCLL) con modificación para la linfocitosis relacionada con el tratamiento, y definida como el tiempo desde la aleatorización hasta la fecha de la primera documentación de la progresión de la enfermedad o la muerte, lo que ocurra primero.

E.5.1.1

Timepoint(s) of evaluation of this end point

1 interim analysis of progression-free survival by independent central review in cohort 1, performed when approximately 79 events (67% of the target number of events at final analysis) from the arms A and B are observed. It is estimated that it will take approximately 25 months to observe 79 events. The final analysis of progression-free survival will take place after 118 events are observed, which is estimated as approximately 35 months from study start.

En la cohorte 1, se llevará a cabo un análisis intermedio de la supervivencia sin progresión, determinada mediante revisión central independiente, cuando se hayan observado aproximadamente 79 casos de supervivencia sin progresión (67 % del número objetivo de casos en el análisis final) en los grupos A y B. Se calcula que se necesitarán aproximadamente 25 meses para observar 79 casos. El análisis final de la supervivencia sin progresión se llevará a cabo una vez que se hayan observado 118 casos, lo cual se calcula que sucederá aproximadamente 35 meses después del inicio del estudio.

E.5.2

Secondary end point(s)

• Overall response rate in cohort 1 defined as the proportion of patients who achieve a complete response, complete response with incomplete bone marrow recovery, partial response, or partial response with lymphocytosis, determined by independent central review and by investigator assessment
• Overall survival in cohort 1 defined as the time from randomization to the date of death due to any reason
• Duration of response in cohort 1 determined by independent central review and by investigator assessment using the iwCLL criteria with modification for treatment-related lymphocytosis, and defined as the time from the date that response criteria are first met to the date that disease progression is objectively documented or death, whichever occurs first
• Progression-free survival in cohort 1 determined by investigator assessment
• Patient-reported outcomes in cohort 1 measured by the EQ-5D-5L and EORTC QLQ-C30 questionnaires
• Overall response rate in cohort 2 (patients with del[17p]) determined by independent central review
• Overall survival in cohort 2
• Progression-free survival in cohort 2 determined by independent central review
• Duration of response in cohort 2 determined by independent central review
• Safety parameters, including AEs, SAEs, clinical laboratory tests, physical exams, and vital signs
• Pharmacokinetic parameters such as apparent clearance of the drug from plasma (CL/F) and AUC0-12

• Tasa de respuesta global en la cohorte 1 definida como la proporción de pacientes que logran una respuesta completa, respuesta completa con recuperación medular incompleta, respuesta parcial o respuesta parcial con linfocitosis, conforme a la revisión central independiente y a la evaluación del investigador
• Supervivencia general en la cohorte 1 definida como el tiempo desde la aleatorización hasta la fecha de la muerte debida a cualquier motivo
• Duración de la respuesta en la cohorte 1 conforme a la revisión central independiente y a la evaluación del investigador usando los criterios del iwCLL con modificación para la linfocitosis relacionada con el tratamiento, y definida como el tiempo desde el momento en que se cumplen por primera vez los criterios de respuesta hasta la fecha en la que se documenta objetivamente por primera vez la progresión de la enfermedad o la muerte, lo que ocurra primero
• Supervivencia sin progresión en la cohorte 1 conforme a la evaluación del investigador
• Resultados comunicados por el paciente en la cohorte 1 medidos por los cuestionarios EQ-5D-5L y QLQ-C30 de la EORTC
• Tasa de respuesta global en la cohorte 2 (pacientes con del[17p]) conforme a la revisión central independiente
• Supervivencia general en la cohorte 2
• Supervivencia sin progresión en la cohorte 2 conforme a la revisión central independiente
• Duración de la respuesta en la cohorte 2 conforme a la revisión central independiente
• Parámetros de seguridad, incluidos los AA, AAG, análisis clínicos, exploraciones físicas y constantes vitales
• Parámetros farmacocinéticos como el aclaramiento plasmático aparente del fármaco (CL/F) y el ABC0-12

E.5.2.1

Timepoint(s) of evaluation of this end point

At time of interim analysis if the PFS comparison between the 2 arms in cohort 1 crosses the stopping boundary. Or at the time of final PFS analysis.

En el momento del análisis provisional, si la comparación de la SSP entre los 2 grupos de la cohorte 1 cruza el límite de detención. O en el momento del análisis final de la SSP.

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

E.6.3

Therapy

E.6.4

Safety

Yes

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

Yes

E.6.7

Pharmacodynamic

E.6.8

Bioequivalence

E.6.9

Dose response

E.6.10

Pharmacogenetic

E.6.11

Pharmacogenomic

E.6.12

Pharmacoeconomic

E.6.13

Others

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

E.7.3

Therapeutic confirmatory (Phase III)

Yes

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

Yes

E.8.1.1

Randomised

Yes

E.8.1.2

Open

Yes

E.8.1.3

Single blind

E.8.1.4

Double blind

E.8.1.5

Parallel group

Yes

E.8.1.6

Cross over

Yes

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

Yes

E.8.2.2

Placebo

E.8.2.3

Other

E.8.2.4

Number of treatment arms in the trial

E.8.3

The trial involves single site in the Member State concerned

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

Yes

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.6.3

If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned

Australia

Austria

Belgium

Canada

Czech Republic

France

Germany

Hungary

Israel

Italy

Korea, Republic of

New Zealand

Poland

Russian Federation

Spain

Sweden

Taiwan

United Kingdom

United States

E.8.7

Trial has a data monitoring committee

Yes

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

LVLS

La última visita del último paciente

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

E.8.9.2

In all countries concerned by the trial months

E.8.9.2

In all countries concerned by the trial days

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

F.1.1.6

Adolescents (12-17 years)

F.1.2

Adults (18-64 years)

Yes

F.1.2.1

Number of subjects for this age range:

F.1.3

Elderly (>=65 years)

Yes

F.1.3.1

Number of subjects for this age range:

374

F.2 Gender

F.2.1

Female

Yes

F.2.2

Male

Yes

F.3 Group of trial subjects

F.3.1

Healthy volunteers

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

Yes

F.3.3.1

Women of childbearing potential not using contraception

F.3.3.2

Women of child-bearing potential using contraception

Yes

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

F.3.3.7

Others

F.4 Planned number of subjects to be included

F.4.1

In the member state

F.4.2

For a multinational trial

F.4.2.1

In the EEA

250

F.4.2.2

In the whole clinical trial

467

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

Patients receiving BGB-3111, who in the opinion of the investigator, continue to benefit from study treatment may continue treatment with BGB-3111 by enrolling on the BGB-3111 Long Term Extension Study.

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2017-12-27

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2017-12-26

P. End of Trial
P.	End of Trial Status	Ongoing

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials